Antibody-Drug Conjugates in Ovarian Cancer: Promises and Challenges

Antibody-Drug Conjugates in Ovarian Cancer: Promises and Challenges

Ovarian cancer (OC) remains one of the most lethal gynecological malignancies globally, often detected at advanced stages which contribute to its high mortality rate. Recurrent and drug-resistant cases further complicate the therapeutic landscape, underscoring the urgent need for innovative treatmen...

Full description

Bibliographic Details
Main Authors:	Marta Nerone, Maria Del Grande, Ilaria Colombo
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2023-10-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/HBT.OH.2023.17.119

Similar Items

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
by: Marta Nerone, et al.
Published: (2022-04-01)

Targeting cancer with antibody-drug conjugates: Promises and challenges
by: Alexis Q. Dean, et al.
Published: (2021-01-01)

Understanding the promising role of antibody drug conjugates in breast and ovarian cancer
by: Ritchu Babbar, et al.
Published: (2023-11-01)

Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease
by: Marta Nerone, et al.
Published: (2023-12-01)

Antibody-Drug Conjugates in Solid Tumors
by: Ilaria Colombo, et al.
Published: (2022-03-01)

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
by: Qing Wei, et al.
Published: (2024-01-01)

Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy
by: Shabnam Malik, et al.
Published: (2024-08-01)

Antibody-Drug Conjugates in Cancer
by: Marcus Vetter
Published: (2024-06-01)

Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
by: Megan Minnix, et al.
Published: (2020-07-01)

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
by: Wen‐Qian Li, et al.
Published: (2021-07-01)

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy
by: Thomas Mehrling, et al.
Published: (2018-02-01)

Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01)

Antibody Drug Conjugates as Cancer Therapeutics
by: Pamela A. Trail
Published: (2013-02-01)

Antibody Drug Conjugates for Cancer Therapy
by: S M Gheibi hayat, et al.
Published: (2017-07-01)

Antibody-drug conjugates for cancer therapy
by: Anna Grzywa
Published: (2021-11-01)

Advances and Limitations of Antibody Drug Conjugates for Cancer
by: Candice Maria Mckertish, et al.
Published: (2021-07-01)

Antibody-drug conjugates in elderly patients with breast cancer
by: Marta Bonotto, et al.
Published: (2025-04-01)

Rabbit derived VL single-domains as promising scaffolds to generate antibody–drug conjugates
by: Ana S. André, et al.
Published: (2023-03-01)

Development of antibody drug conjugates for cancer therapy
by: Alif Sufiyan Ali
Published: (2018)

Antibody-drug conjugates combinations in cancer treatment
by: Giulia Pretelli, et al.
Published: (2024-06-01)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
by: Guolan Lu, et al.
Published: (2020-11-01)

Computed Tomography–Based Body Composition in Patients With Ovarian Cancer: Association With Chemotoxicity and Prognosis
by: Maria Del Grande, et al.
Published: (2021-11-01)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
by: Hyunbo Shim
Published: (2020-02-01)

Antibody drug conjugates: hitting the mark in pancreatic cancer?
by: Nicole L. Wittwer, et al.
Published: (2023-10-01)

Antibody-drug conjugates in breast cancer: advances and prospects
by: Zhiqiang Shi, et al.
Published: (2025-02-01)

Development of antibody‐drug conjugates in cancer: Overview and prospects
by: Dan‐Yun Ruan, et al.
Published: (2024-01-01)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
by: Chi Hun Song, et al.
Published: (2023-11-01)

Antibody-drug conjugates: the clinical development in gastric cancer
by: Yingze Zhu, et al.
Published: (2023-05-01)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
by: Hany E. Marei, et al.
Published: (2022-08-01)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01)

ANTIBODY DRUG CONJUGATES (ADCS)
by: E. Terpos
Published: (2023-05-01)

Introduction to Antibody-Drug Conjugates
by: Mark C. Pettinato
Published: (2021-10-01)

Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives
by: Keqiang Li, et al.
Published: (2023-12-01)

Diverse Roles of Antibodies in Antibody–Drug Conjugates
by: Aiko Yamaguchi, et al.
Published: (2025-01-01)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
by: Mo Wu, et al.
Published: (2022-11-01)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
by: Andrea D’Arienzo, et al.
Published: (2023-08-01)

Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
by: Matteo Perra, et al.
Published: (2025-01-01)

Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer
by: Mizuki Kanda, et al.
Published: (2023-01-01)

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
by: Guilherme Nader-Marta, et al.
Published: (2023-07-01)

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
by: Jun He, et al.
Published: (2024-08-01)